Literature DB >> 12808890

Miglustat. Oxford GlycoSciences/Actelion.

Robin H Lachmann1.   

Abstract

Oxford GlycoSciences and Actelion have developed and launched miglustat (OGT-918; Vevesca; Zavesca) for the treatment of type 1 Gaucher disease. Miglustat is an orally administered small-molecule glucosylceramide glucosyltransferase inhibitor licensed from Searle, and it is also in development for the treatment of other glycolipid storage disorders such as Tay-Sachs, Fabry and Niemann-Pick type C diseases. In November 2002, miglustat received EU approval for the treatment of Gaucher disease and was launched in the UK in March 2003 by Actelion. At this time, additional EU launches were expected over the next few months.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12808890

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  12 in total

Review 1.  Ashkenazi Jewish genetic disorders.

Authors:  Joel Charrow
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

Review 2.  Glycosphingolipidoses: beyond the enzymatic defect.

Authors:  Annick Raas-Rothschild; Irene Pankova-Kholmyansky; Yaacov Kacher; Anthony H Futerman
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

3.  Disorders of cholesterol metabolism and their unanticipated convergent mechanisms of disease.

Authors:  Frances M Platt; Christopher Wassif; Alexandria Colaco; Andrea Dardis; Emyr Lloyd-Evans; Bruno Bembi; Forbes D Porter
Journal:  Annu Rev Genomics Hum Genet       Date:  2014       Impact factor: 8.929

Review 4.  Secondary alterations of sphingolipid metabolism in lysosomal storage diseases.

Authors:  Alessandro Prinetti; Simona Prioni; Elena Chiricozzi; Edward H Schuchman; Vanna Chigorno; Sandro Sonnino
Journal:  Neurochem Res       Date:  2011-01-05       Impact factor: 3.996

5.  Substrate reduction therapy of glycosphingolipid storage disorders.

Authors:  Johannes M F G Aerts; Carla E M Hollak; Rolf G Boot; Johanna E M Groener; Mario Maas
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

Review 6.  Deregulated sphingolipid metabolism and membrane organization in neurodegenerative disorders.

Authors:  Marco Piccinini; Federica Scandroglio; Simona Prioni; Barbara Buccinnà; Nicoletta Loberto; Massimo Aureli; Vanna Chigorno; Elisa Lupino; Giovanni DeMarco; Annarosa Lomartire; Maria Teresa Rinaudo; Sandro Sonnino; Alessandro Prinetti
Journal:  Mol Neurobiol       Date:  2010-02-03       Impact factor: 5.590

Review 7.  Lysosomal storage diseases.

Authors:  Frances M Platt; Alessandra d'Azzo; Beverly L Davidson; Elizabeth F Neufeld; Cynthia J Tifft
Journal:  Nat Rev Dis Primers       Date:  2018-10-01       Impact factor: 52.329

8.  Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.

Authors:  Eugen Ruckhäberle; Thomas Karn; Lars Hanker; Regine Gätje; Dirk Metzler; Uwe Holtrich; Manfred Kaufmann; Achim Rody
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-17       Impact factor: 4.553

9.  The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses.

Authors:  Marlieke L M Jongsma; Antonius A de Waard; Matthijs Raaben; Tao Zhang; Birol Cabukusta; René Platzer; Vincent A Blomen; Anastasia Xagara; Tamara Verkerk; Sophie Bliss; Xiangrui Kong; Carolin Gerke; Lennert Janssen; Elmer Stickel; Stephanie Holst; Rosina Plomp; Arend Mulder; Soldano Ferrone; Frans H J Claas; Mirjam H M Heemskerk; Marieke Griffioen; Anne Halenius; Hermen Overkleeft; Johannes B Huppa; Manfred Wuhrer; Thijn R Brummelkamp; Jacques Neefjes; Robbert M Spaapen
Journal:  Immunity       Date:  2020-12-02       Impact factor: 31.745

10.  Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease.

Authors:  Elena-Raluca Nicoli; Nada Al Eisa; Celine V M Cluzeau; Christopher A Wassif; James Gray; Kathryn R Burkert; David A Smith; Lauren Morris; Stephanie M Cologna; Cody J Peer; Tristan M Sissung; Constantin-Daniel Uscatu; William D Figg; William J Pavan; Charles H Vite; Forbes D Porter; Frances M Platt
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.752
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.